医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Invida Changes Name to Menarini Asia-Pacific

2012年12月07日 AM10:25
このエントリーをはてなブックマークに追加


 

SINGAPORE

Invida Holdings Private Limited, the leading biopharmaceutical commercialization company in Asia-Pacific, is pleased to announce a name change to A. Menarini Asia-Pacific Holdings Pte. Ltd. (“Menarini Asia-Pacific”) effective immediately. The brand transformation reflects its alignment with parent, Menarini Group, and allows for the promotion of a single, unified brand in the global marketplace. The name change will also progressively take place across its other offices within the region in 2013.

“Since Invida’s acquisition by Menarini Group in November 2011, we have been zealously working to integrate the culture and operations of the two companies, and the name change is a logical step in the process. We are proud to build on Menarini’s more than 125 years of company history, bringing Menarini’s brands and expertise into our already established operations in Asia-Pacific. This will accelerate our achievement of the vision to become the leading provider of important healthcare brands to improve the lives of people in the region”, said John A. Graham, Chief Executive Officer of Menarini Asia-Pacific.

Menarini Group is Italy’s largest biopharmaceutical company, with 2011 revenue in excess of US$3.9billion, 15,000 employees and a global presence in over 100 countries. As a fully integrated pharmaceutical company, Menarini Asia-Pacific is able to tap into Menarini Group’s research & development and manufacturing capabilities, as well as leverage Menarini’s collective strength to pursue the right opportunities for growth in the Asia-Pacific region.

Menarini Group was the honoured recipient of the ‘Best Italian Multinational Corporation in Singapore’ 2012 award at the Annual Gala Dinner of the Italian Chamber of Commerce in Singapore (“ICCS”) held last evening. The ICCS has been running the Annual Business Awards since 2009 to recognise the outstanding contributions of Italian Companies. The award for ‘Best Italian Multinational Corporation in Singapore’ is reserved for eligible Italian corporations with significant investments and activities in Singapore or, through Singapore, into the region.

“We are honoured to be the recipient of this award by the Italian Chamber of Commerce in Singapore. It is testament to the successful union of Invida and Menarini, and the immense confidence we have in the growth potential of the Asia-Pacific region. Singapore is central to the Menarini Group’s plans in the region and we are fully committed to expand the future of our business in this region”, said Dr. Alberto Giovanni Aleotti, Member of Board, Menarini Group.

About Menarini Asia-Pacific Group (Formerly Invida Group)

Menarini Asia-Pacific, a fully owned member of the Menarini Group, improves the lives of patients in Asia-Pacific by commercializing differentiated pharmaceutical and OTC brands. This is done through proven brand marketing and sales know-how, strong expertise across a number of key therapeutic categories and deep experience in all major Asia-Pacific markets. Comprehensive functional capabilities provide rapid market access delivered by a passionate team of sales and marketing professionals.

With over 3,300 employees in 13 key markets in Asia Pacific, Menarini Asia-Pacific operates across the commercial value chain from regulatory approval and product launch to lifecycle management. Partnering is an integral component of Menarini Asia-Pacific’s business model. We collaborate closely through long-term relationships with selected partners in developing effective strategies and putting our extensive experience behind maximizing the potential of the assets entrusted to us.

For further information please visit www.menariniapac.com

About Menarini Group

Menarini is an international pharmaceutical company which, with a 2011 consolidated worldwide turnover of more than 3 billion Euro, ranks 17th in Europe and 34th world-wide.

Menarini’s territorial presence covers more than 100 countries in Europe, Africa, Asia, Australia and Latin America, with 15,000 headcount. Menarini was founded 125 years ago and currently markets products for the most important therapeutic fields: respiratory, cardiovascular, gastroenterology, oncology, metabolism, antibiotics, diabetes, anti-inflammatories and analgesics.

The Menarini Group has always pursued two strategic objectives: Research and Internationalisation, both of which have allowed it to achieve outstanding results in today’s global market and invest in the research of innovative drugs, making them available to patients all around the world.

For further information please visit:www.menarini.com

CONTACT

Hill + Knowlton Strategies
Rosemary Hayes, +65 6390 3323
rosemary.hayes@hkstrategies.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表
  • Intercell USA Changes Name to Valneva USA, Inc. and Expands Commercial Presence
  • ADC Therapeutics präsentiert Zwischenergebnisse aus Phase-I-Studie zu neuartigem Antikörper-Wirkstoff-Konjugat ADCT-402